Under the Radar: Amylyx Stock Surges on Positive Trial Results

Dow Jones

Aug 18

Amylyx Pharmaceuticals shares rose more than 40% Tuesday after the company announced that its experimental treatment for a condition called post-bariatric hypoglycemia, or PBH, reduced the rate of significant blood-sugar crashes by 55% compared with a placebo in a late-stage trial.

PBH, which sets in after a person undergoes bariatric surgery for weight loss, causes severe blood sugar drops after eating and affects roughly 160,000 in the U.S. There are currently no treatments approved by the Food and Drug Administration.

Cambridge, Mass.-based Amylyx plans to submit the drug to the FDA for approval by the end of 2026, and is aiming for a potential commercial launch next year.

The results were "beyond anything we were dreaming of," said Amylyx co-Chief Executive Justin Klee. "We may really be able to make an impact on people's lives."

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2660496853"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2660496853\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2660496853?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 23:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660496853","market":"sh","top_or_hot":-1,"title":"Under the Radar: Amylyx Stock Surges on Positive Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     <a href=\"https://laohu8.com/S/AMLX\">Amylyx Pharmaceuticals</a> shares rose more than 40% Tuesday after the company announced that its experimental treatment for a condition called post-bariatric hypoglycemia, or PBH, reduced the rate of significant blood-sugar crashes by 55% compared with a placebo in a late-stage trial. \n</p>\n<p>\n     PBH, which sets in after a person undergoes bariatric surgery for weight loss, causes severe blood sugar drops after eating and affects roughly 160,000 in the U.S. There are currently no treatments approved by the Food and Drug Administration. \n</p>\n<p>\n     Cambridge, Mass.-based Amylyx plans to submit the drug to the FDA for approval by the end of 2026, and is aiming for a potential commercial launch next year. \n</p>\n<p>\n     The results were \"beyond anything we were dreaming of,\" said Amylyx co-Chief Executive Justin Klee. \"We may really be able to make an impact on people's lives.\" \n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Under the Radar: Amylyx Stock Surges on Positive Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnder the Radar: Amylyx Stock Surges on Positive Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-08-18 23:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     <a href=\"https://laohu8.com/S/AMLX\">Amylyx Pharmaceuticals</a> shares rose more than 40% Tuesday after the company announced that its experimental treatment for a condition called post-bariatric hypoglycemia, or PBH, reduced the rate of significant blood-sugar crashes by 55% compared with a placebo in a late-stage trial. \n</p>\n<p>\n     PBH, which sets in after a person undergoes bariatric surgery for weight loss, causes severe blood sugar drops after eating and affects roughly 160,000 in the U.S. There are currently no treatments approved by the Food and Drug Administration. \n</p>\n<p>\n     Cambridge, Mass.-based Amylyx plans to submit the drug to the FDA for approval by the end of 2026, and is aiming for a potential commercial launch next year. \n</p>\n<p>\n     The results were \"beyond anything we were dreaming of,\" said Amylyx co-Chief Executive Justin Klee. \"We may really be able to make an impact on people's lives.\" \n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMLX","symbol_name":"Amylyx Pharmaceuticals","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2660496853","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660496853","pubTimestamp":1787068380,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Amylyx Pharmaceuticals shares rose more than 40% Tuesday after the company announced that its experimental treatment for a condition called post-bariatric hypoglycemia, or PBH, reduced the rate of sig","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMLX":"Amylyx Pharmaceuticals","BK4007":"制药"},"translate_title":"雷达下：Amylyx 股价因积极的试验结果而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMLX":0.9},"content_text":"Amylyx Pharmaceuticals shares rose more than 40% Tuesday after the company announced that its experimental treatment for a condition called post-bariatric hypoglycemia, or PBH, reduced the rate of significant blood-sugar crashes by 55% compared with a placebo in a late-stage trial. \n\n\n     PBH, which sets in after a person undergoes bariatric surgery for weight loss, causes severe blood sugar drops after eating and affects roughly 160,000 in the U.S. There are currently no treatments approved by the Food and Drug Administration. \n\n\n     Cambridge, Mass.-based Amylyx plans to submit the drug to the FDA for approval by the end of 2026, and is aiming for a potential commercial launch next year. \n\n\n     The results were \"beyond anything we were dreaming of,\" said Amylyx co-Chief Executive Justin Klee. \"We may really be able to make an impact on people's lives.\"","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}